| Wu, Depei |
NCT02323022: Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) |
|
|
| Completed | 3 | 618 | RoW | IAC regimen, IA regimen | The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia | 03/20 | 01/22 | | |
NCT03719534: Haplo HCT vs Haplo-cord HCT for Patients With AML |
|
|
| Completed | 3 | 134 | RoW | haplo-HCT, haplo-cord HCT | The First Affiliated Hospital of Soochow University, Zhejiang University, The Second People's Hospital of Huai'an, Soochow Hopes Hematology Hospital, Hygeia Suzhou Yongding Hospital | Hematopoietic Stem Cell Transplantation, Haplo-identical Donor, Cord Blood Unit, Acute Myeloid Leukemia | 12/22 | 03/23 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
| Recruiting | 2/3 | 120 | RoW | Eltrombopag 25 MG Oral Tablet, TPO-RA, Supportive care, support | The First Affiliated Hospital of Soochow University | Stem Cell Transplant Complications | 07/25 | 07/27 | | |
NCT04539444: A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma |
|
|
| Recruiting | 2 | 10 | RoW | CD19/22 CART, Tislelizumab, PD-1 inhibitor | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | 02/22 | 02/23 | | |
NCT04930562: Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD) |
|
|
| Completed | 2 | 30 | RoW | BN101, belumosudil, KD025 | BioNova Pharmaceuticals (Shanghai) LTD. | GVHD, Chronic | 06/22 | 12/22 | | |
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) |
|
|
| Enrolling by invitation | 2 | 64 | RoW | ABSK021 | Abbisko Therapeutics Co, Ltd | cGvHD | 10/26 | 12/26 | | |
| Recruiting | 2 | 20 | RoW | Humanized CD7 CAR-T cells | The First Affiliated Hospital of Soochow University, PersonGen BioTherapeutics (Suzhou) Co., Ltd., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Affiliated Hospital of Jiangnan University, The Affiliated Zhongshan Hospital of Dalian University, The First Affiliated Hospital of Dalian Medical University | Refractory and Relapsed T Cell Lymphoma | 08/23 | 08/24 | | |
NCT05510505: GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT |
|
|
| Recruiting | 2 | 100 | RoW | CD20 monoclonal antibody, allogeneic hematopoietic stem cell transplantation, ATG | The First Affiliated Hospital of Soochow University | Aplastic Anemia | 09/23 | 12/25 | | |
NCT05182957: Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma |
|
|
| Recruiting | 2 | 40 | RoW | Anti-PD-1 monoclonal antibody, Anti-PD-1 antibody, Lenalidomide, Immunomodulator, Azacitidine, 5-Ladakamycin | The First Affiliated Hospital of Soochow University | Relapsed/Refractory Peripheral T-cell Lymphoma | 12/23 | 12/23 | | |
NCT05322330: Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 20 | RoW | Selinexor, XPO-1 Inhibitor, Flu, Fludarabine, CTX, Cyclophosphamide, CAR-T, Chimeric antigen receptor-modified T (CAR-T) cell therapy | The First Affiliated Hospital of Soochow University, West China Hospital, The General Hospital of Western Theater Command PLA, The Affiliated People's Hospital of Ningbo University Ningbo Yinzhou People's Hospital Community, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Yixing People's Hospital, Affiliated Hospital of Jiangnan University, Wuxi Second People's Hospital | Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | 02/24 | 02/24 | | |
NCT06394011: Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients |
|
|
| Recruiting | 2 | 60 | RoW | venetoclax, azacitidine and HAAG regimen | The First Affiliated Hospital of Soochow University | Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia | 05/26 | 12/26 | | |
NCT05241106: A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | 2 | 15 | RoW | HYML-122 | Tarapeutics Science Inc. | Relapsed or Refractory Acute Myeloid Leukemia (AML) | 12/25 | 06/26 | | |
NCT05241093: A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | 2 | 18 | RoW | HYML-122; cytarabine | Tarapeutics Science Inc. | Relapsed or Refractory Acute Myeloid Leukemia (AML) | 12/24 | 06/25 | | |
NCT06367114: Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) |
|
|
| Not yet recruiting | 2 | 50 | RoW | ssCART-19, Fludarabine, Cyclophosphamide | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University, Peking University People's Hospital | Relapsed or Refractory Acute Lymphoblastic Leukemia | 09/24 | 12/25 | | |
NCT06093841: Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL |
|
|
| Not yet recruiting | 2 | 46 | RoW | Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide | Shanghai Ming Ju Biotechnology Co., Ltd. | Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma | 08/24 | 02/27 | | |
NCT06078306: CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). |
|
|
| Recruiting | 2 | 20 | RoW | Azacitidine Injection, Azacitidine, Venetoclax, ABT-199, CD19CD22 CAR-T, GDC-0199 | The First Affiliated Hospital of Soochow University | B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia | 09/24 | 09/25 | | |
NCT05809167: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT |
|
|
| Recruiting | 2 | 55 | RoW | VEN+AZA+Modified BUCY | The First Affiliated Hospital of Soochow University | Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia | 01/25 | 01/26 | | |
NCT05823714: Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT |
|
|
| Recruiting | 2 | 70 | RoW | VEN+AZA+Modified BUCY | The First Affiliated Hospital of Soochow University | Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome | 01/25 | 01/26 | | |
NCT05312476: Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 12 | RoW | Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets, Chimeric antigen receptor-modified T (CAR-T) cell therapy | The First Affiliated Hospital of Soochow University | Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | 02/25 | 02/25 | | |
NCT04835870: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
|
|
| Recruiting | 2 | 78 | RoW | Zanubrutinib, BTK inhibitors, Rituximab, MabThera, Cyclophosphamide, CTX, Doxorubicin, ADM, Vincristine, VCR, Prednisone, Prednisonum | The First Affiliated Hospital of Soochow University | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | 10/25 | 10/25 | | |
| Active, not recruiting | 1/2 | 196 | RoW | CAR T-cell therapy | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The Second People's Hospital of Huai'an, Third Military Medical University | Acute Lymphoblastic Leukemia with Failed Remission | 08/24 | 12/25 | | |
NCT03455972: Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT |
|
|
| Recruiting | 1/2 | 15 | RoW | anti-CD19 and anti-BCMA CAR, Immunomodulatory drugs, IMiDs | The First Affiliated Hospital of Soochow University | Safety and Efficacy | 12/21 | 12/23 | | |
| Recruiting | 1/2 | 190 | RoW | AK117, Azacitidine | Akeso | Myelodysplastic Syndrome | 05/23 | 05/24 | | |
NCT04941404: A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD) |
|
|
| Active, not recruiting | 1/2 | 13 | RoW | TQ05105 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Glucocorticoid-Refractory aGVHD | 07/23 | 12/24 | | |
NCT05140616: Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD |
|
|
| Recruiting | 1/2 | 20 | RoW | Chidamide | The First Affiliated Hospital of Soochow University | Safety and Efficacy | 05/24 | 05/24 | | |
NCT04485052: Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia |
|
|
| Suspended | 1/2 | 222 | RoW | IBI188, Azacitidine, Decitabine | Innovent Biologics (Suzhou) Co. Ltd. | Acute Myeloid Leukemia | 06/24 | 12/24 | | |
NCT05381662: CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment |
|
|
| Recruiting | 1/2 | 10 | RoW | CD19 CAR-T cells and CD19 positive feeder T cells | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital of Soochow University | Acute Lymphoblastic Leukemia in Remission | 08/24 | 12/25 | | |
NCT05647512: Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases |
|
|
| Withdrawn | 1/2 | 380 | NA | LM-305, Dexamethasone | LaNova Medicines Limited | Relapsed or Refractory Multiple Myeloma, Other Plasma Cell Diseases | 12/24 | 12/25 | | |
NCT05768529: Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 1/2 | 100 | RoW | U16 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Relapsed or Refractory Non-Hodgkin's Lymphoma | 12/24 | 12/26 | | |
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia |
|
|
| Recruiting | 1/2 | 90 | RoW | BN104 | BioNova Pharmaceuticals (Shanghai) LTD. | ALL, Adult, AML, Adult | 06/26 | 06/27 | | |
NCT05148442: A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor |
|
|
| Terminated | 1a/1b | 1 | RoW | IBI322 | Innovent Biologics (Suzhou) Co. Ltd. | Myeloid Tumor | 06/23 | 08/23 | | |
NCT05270928: Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001# |
|
|
| Completed | 1 | 6 | RoW | IBI346 | The First Affiliated Hospital of Soochow University, Innovent Biologics (Suzhou) Co. Ltd. | Relapsed/Refractory Multiple Myeloma | 12/22 | 05/23 | | |
NCT06234904: Study of IBR733 Cell Injection in Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 1 | 18 | RoW | IBR733 Cell Injection | Imbioray (Hangzhou) Biomedicine Co., Ltd., The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia | 02/25 | 08/25 | | |
NCT06696833: Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 18 | RoW | QH10304-BAL-01, Fludarabine, Cyclophosphamide | The First Affiliated Hospital of Soochow University | B-Cell Acute Lymphoblastic Leukemia, Adult | 12/25 | 12/25 | | |
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia |
|
|
| Completed | 1 | 46 | US, RoW | APG2575 400 mg, APG2575 600 mg, APG2575 800 mg | Ascentage Pharma Group Inc. | Waldenstrom Macroglobulinemia | 02/24 | 02/24 | | |
NCT05641259: A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML |
|
|
| Recruiting | 1 | 198 | RoW | LP-108, Azacitidine | Guangzhou Lupeng Pharmaceutical Company LTD. | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 12/24 | 12/25 | | |
NCT05691153: ThisCART19A for B-NHL Relapsed After Auto-CAR T |
|
|
| Recruiting | 1 | 20 | RoW | ThisCART19A with Dose Level 1, ThisCART19A with 2×10^6 cells/kg, ThisCART19A with Dose Level 2, ThisCART19A with 3×10^6 cells/kg | The First Affiliated Hospital of Soochow University, Fundamenta Therapeutics, Ltd. | CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | 11/25 | 11/25 | | |
| Recruiting | 1 | 20 | RoW | Treatment | The First Affiliated Hospital of Soochow University, Fundamenta Therapeutics, Ltd. | CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL | 11/25 | 11/25 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT05587881: Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation |
|
|
| Withdrawn | N/A | 400 | RoW | COVID-19 vaccine(donor), COVID-19 vaccine(patient) | The First Affiliated Hospital of Soochow University | Hematologic Diseases | 11/23 | 11/23 | | |
NCT03148743: Fecal Microbiota Transplantation in Gut aGVHD Treated |
|
|
| Recruiting | N/A | 50 | RoW | Fecal microbiota | The First Affiliated Hospital of Soochow University | Acute-graft-versus-host Disease | 12/25 | 12/25 | | |
| Recruiting | N/A | 100 | RoW | | The First Affiliated Hospital of Soochow University | Graft Versus Host Disease | 12/26 | 12/26 | | |
NCT06548958: A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases |
|
|
| Recruiting | N/A | 40 | RoW | Second Stem Cell Transplantation (SCT2) | The First Affiliated Hospital of Soochow University | Malignant Hematological Diseases | 03/27 | 06/27 | | |
NCT05852028: A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma |
|
|
| Recruiting | N/A | 250 | RoW | Selinexor, XPO1 inhibitor | Ruijin Hospital | Lymphoma, DLBCL, T Cell Lymphoma | 10/24 | 10/25 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
NCT04923789: A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma |
|
|
| Recruiting | N/A | 60 | RoW | | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | 03/22 | 03/23 | | |
| qi, xiaofei |
NCT03148743: Fecal Microbiota Transplantation in Gut aGVHD Treated |
|
|
| Recruiting | N/A | 50 | RoW | Fecal microbiota | The First Affiliated Hospital of Soochow University | Acute-graft-versus-host Disease | 12/25 | 12/25 | | |
| Recruiting | N/A | 100 | RoW | | The First Affiliated Hospital of Soochow University | Graft Versus Host Disease | 12/26 | 12/26 | | |
